Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways

- Imatinib resistance leads to MRP1-5, ABCA2 and ABCG2 transporters overexpression.
- Celecoxib and imatinib co-treatment inhibited the expression of ABC transporters.
- Ras-Raf-Mek-Erk-CREB and GSK-3β-β-catenin-TCF4-LEF1 pathways are inhibited.
- Celecoxib sensitizes resistant cells to imatinib by inhibiting ABC transporters.